SOLANA BEACH, Calif., Aug. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets Group: IMMY), a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has created a Science and Regulatory Advisory Board and that Dr. Gerald Yakatan has become the inaugural member of the newly created board. The Imprimis Science and Regulatory Advisory Board will be comprised of scientists and pharmaceutical industry thought leaders who have demonstrated a record of success in developing drugs for clearance by the US Food & Drug Administration. The mission of the Imprimis Science and Regulatory Advisory Board will be to advise Imprimis management on the future development of the patented Accudel topical drug delivery platform and to assist in the design and execution of the planned Phase 3 clinical studies for Imprimis's topical 10% ketoprofen anti-inflammatory drug called Impracor.
Imprimis Pharmaceuticals, Inc. CEO Mark L. Baum stated, "The Imprimis team welcomes Dr. Yakatan to our newly created Science and Regulatory Advisory Board. Jerry is an impressive figure in the pharmaceutical industry, experiencing success in the academic world at University of Texas, Austin where he served as a Professor and eventually as Chairman of the Pharmaceutics Department, and later in industry where in 1980 he joined Warner Lambert as Director of Pharmacokinetics and Drug Metabolism and eventually was promoted to Vice President of Product Development Worldwide. At Warner Lambert, Dr. Yakatan participated in the development of several drug products including Lopid®, Lipitor®, Eryc® Accupril®, Neurontin® and the Benadryl® cough line. In 1998, Dr. Yakatan began his tenure at Avanir Pharmaceuticals as President and Chief Executive Officer where he led the development efforts of Nuedexta™ and where he was responsible for the regulatory approval and comm
|SOURCE Imprimis Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved